These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 9254703)

  • 1. Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects.
    Grassi G; Forlino A; Marini JC
    Nucleic Acids Res; 1997 Sep; 25(17):3451-8. PubMed ID: 9254703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts.
    Dawson PA; Marini JC
    Nucleic Acids Res; 2000 Oct; 28(20):4013-20. PubMed ID: 11024182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
    Phylactou LA; Tsipouras P; Kilpatrick MW
    Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cleavage of full-length beta APP mRNA by hammerhead ribozymes.
    Denman RB
    Nucleic Acids Res; 1993 Aug; 21(17):4119-25. PubMed ID: 8371986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mutation-independent therapeutic strategem for osteogenesis imperfecta.
    Millington-Ward S; O'Neill B; Kiang AS; Humphries P; Kenna PF; Farrar GJ
    Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):537-42. PubMed ID: 10645780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced intracellular availability and survival of hammerhead ribozymes increases target ablation in a cellular model of osteogenesis imperfecta.
    Smicun Y; Kilpatrick MW; Florer J; Toudjarska I; Wu G; Wenstrup RJ; Tsipouras P
    Gene Ther; 2003 Nov; 10(24):2005-12. PubMed ID: 14566359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates.
    Sioud M
    Nucleic Acids Res; 1997 Jan; 25(2):333-8. PubMed ID: 9016562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.
    Sullivan JM; Pietras KM; Shin BJ; Misasi JN
    Mol Vis; 2002 Apr; 8():102-13. PubMed ID: 11961505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation in mesenchymal progenitor cells of a mutation-independent ex vivo approach to gene therapy for osteogenesis imperfecta.
    Millington-Ward S; Allers C; Tuohy G; Conget P; Allen D; McMahon HP; Kenna PF; Humphries P; Farrar GJ
    Hum Mol Genet; 2002 Sep; 11(19):2201-6. PubMed ID: 12217948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of a hammerhead ribozyme specifically downregulates mutant type I collagen mRNA in a murine model of osteogenesis imperfecta.
    Toudjarska I; Kilpatrick MW; Niu J; Wenstrup RJ; Tsipouras P
    Antisense Nucleic Acid Drug Dev; 2001 Oct; 11(5):341-6. PubMed ID: 11763351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular RNA cleavage by the hairpin ribozyme.
    Seyhan AA; Amaral J; Burke JM
    Nucleic Acids Res; 1998 Aug; 26(15):3494-504. PubMed ID: 9671810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of structure in a long target RNA on ribozyme cleavage efficiency.
    Campbell TB; McDonald CK; Hagen M
    Nucleic Acids Res; 1997 Dec; 25(24):4985-93. PubMed ID: 9396806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors altering ribozyme-mediated cleavage of tumor necrosis factor-alpha mRNA in vitro.
    Kisich KO; Freedland SJ; Erickson KL
    Biochem Biophys Res Commun; 1997 Jul; 236(1):205-11. PubMed ID: 9223453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cleavage of viral RNA and inhibition of viral translation by hepatitis C virus RNA-specific hammerhead ribozyme in vitro.
    Ohkawa K; Yuki N; Kanazawa Y; Ueda K; Mita E; Sasaki Y; Kasahara A; Hayashi N
    J Hepatol; 1997 Jul; 27(1):78-84. PubMed ID: 9252077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and specificity of hammerhead ribozymes against calretinin mRNA.
    Ellis J; Rogers J
    Nucleic Acids Res; 1993 Nov; 21(22):5171-8. PubMed ID: 8255773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa.
    Drenser KA; Timmers AM; Hauswirth WW; Lewin AS
    Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):681-9. PubMed ID: 9538873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended target-site specificity for a hammerhead ribozyme.
    Perriman R; Delves A; Gerlach WL
    Gene; 1992 Apr; 113(2):157-63. PubMed ID: 1572538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of HIV-specific ribozyme activity by self-cleavage.
    Ventura M; Wang P; Ragot T; Perricaudet M; Saragosti S
    Nucleic Acids Res; 1993 Jul; 21(14):3249-55. PubMed ID: 8341599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between tumour necrosis factor alpha ribozyme and cellular proteins. Involvement in ribozyme stability and activity.
    Sioud M
    J Mol Biol; 1994 Oct; 242(5):619-29. PubMed ID: 7932719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of hammerhead ribozyme catalysis by glyceraldehyde-3-phosphate dehydrogenase.
    Sioud M; Jespersen L
    J Mol Biol; 1996 Apr; 257(4):775-89. PubMed ID: 8636981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.